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ABSTRACT
Investigation of Magnetic Resonance Imaging and Spectroscopy for the Detection of
Breast Cancer
by
Robert Thomas Etnire
Dr. Phillip W. Patton, Examination Committee Chair
Associate Professor of Health Physics
University of Nevada, Las Vegas
Magnetic resonance imaging (MRI) of the breast offers an alternative to screening
mammography which may benefit those women at high risk for breast cancer, women
under the age of 40, and those with dense breast tissue. One concern with MRI is the
number of high false positives. Coupling MRI with magnetic resonance spectroscopy
(MRS) may lower the number of false positives, and thus improve the diagnostic
capabilities of MRI for the clinician. MRS for breast imaging focuses on the total choline
containing compounds in the spectra in the suspected breast lesion to analyze areas of
concern. The results of the study indicate that MRI helps differentiate potential lesions in
the breast from healthy tissue, which is clearly seen in scans containing contrast. Also,
MRS helped to confirm if a lesion is malignant by determining the SNR of the lesions,
with an SNR of greater than or equal to 2.0 indicating malignancy.
Keywords; magnetic resonance imaging, magnetic resonance spectroscopy, breast,
mammography
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CHAPTER 1

INTRODUCTION
Effectively treating breast cancer continues to be an extremely difficult task. Imaging
modalities and radiation therapy work jointly in order to accurately locate and then
effectively treat tumors. While current therapies can be effective, they generally are
unsuccessful in changing prognosis in the more common cancers (Allen et al. 2001). The
clinical and pathological findings and the type of treatment to be performed varies with
each individual patient. The effectiveness of different imaging modalities in detailing the
various breast regions impacts the diagnosis and subsequent treatment options.
The American Cancer Society has issued new recommendations for women at
different levels of risk of breast cancer (Saslow et al. 2007). The recommendations for
the use of screening MRI is for those women with approximately 20-25% or greater
increased lifetime risk of developing a form of breast cancer. This includes women with
a family history of breast or ovarian cancer and women who have received previous
treatment with chest irradiation, such as for Hodgkin's disease.

In addition, a recent

study found that MRI can detect cancer in the contralateral breast that may be missed by
mammography, further enhancing the need for MRI (Lehman et al. 2007).
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Anatomy of the Breast
The breasts rest on the pectoralis major, the chest muscle that covers the ribs. They
are supported by and attached to the front of the chest wall on both sides of the sternum
by ligaments (National Cancer Institute 2006). Even though the breasts sit on a major
chest muscle, it has no muscle tissue itself. It is made up of a layer of fat that surrounds
the glands and extends throughout the breast. Each breast is made up of approximately
15-20 lobes (National Cancer Institute 2007a). The lobes are made up of several smaller
lobules. At the end of the lobules, there are tiny bulb-like glands where the milk is
produced (National Cancer Institute 2006). The milk flows from the lobules through the
ducts to the nipple. The fat that covers the lobes is what gives the breast its size and
shape. Figure 1 details the anatomy of the breast.

Nipple surface
Areola

Fatty tissue

Figure 1. Detailed anatomy of the breast (National Cancer Institute 2006).
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The breasts also contain lymph vessels which lead to the lymph nodes (National
Cancer Institute 2007a). There are groups of lymph nodes located near the breast in the
axilla, above the collarbone, behind the sternum, and other various locations throughout
the body.

Figure 2 illustrates the locations of lymph nodes in and surrounding the

breasts. Breast tissue and breast cancer both appear bright when using mammography,
which is part of the problem in detecting breast cancer using screening mammography.

Lobules
Lobe
Ducts
" Nipple "
Areola
Fat
Lympli
nodes

Lymph
vessels

Figure 2. Lymph nodes in and surrounding the breast (National Cancer Institute 2007a).

Breast Cancer Statistics
The main locations of breast cancer include the breast or chest wall, the axilla, and
the ipsilateral supraclavicular and internal mammary lymph nodes.

Breast cancer

typically starts in the ducts and then spreads to the lobules and lobes, and finally to the
3

lymph nodes. The number of breast cancer incidences from 2000-2003 was 199,479 for
invasive cases and 44,913 for in situ cases (National Cancer Institute 2007b). Table 1
details the number of incidences by age and type. Using the previous data for 2005, the
American Cancer Society estimated 211,240 new cases of invasive breast cancer would
be diagnosed as well as 58,490 new cases of in situ breast cancer among women per year
(American Cancer Society 2005). As a result of these case estimates, the American
Cancer Society estimated 40,410 deaths from breast cancer yearly. Table 2 details the
estimated number of new breast cancer cases and deaths in women by age for 2005.
The incomplete killing of malignant cancer cells that have spread throughout the body
is a major failing in the management of breast cancer (Allen et al. 2003). There are
several different options available for the treatment of breast cancer, such as
chemotherapy, surgery, radiation therapy, and hormone therapy. Because of the different
treatment options and the ongoing increase in breast cancer cases each year, an effective
no/minimal risk imaging modality is needed in order to clearly identify tumors in and
around the breast, so an effective treatment process can be implemented.

Table 1. Age Distribution (%) of breast cancer cases by site for all races, 2000-2003
(National Cancer Institute, 2007b).
Age
Site
<20 20-34 35-44 45-54 55-64 65-74 75-84 >85 All Ages Cases
Invasive 0.0
1.9
10.6 22.1 22.8 20.4 16.8 5.4
100.0 199,479
In situ
0.0
0.8
44,913
11.5 27.6 25.0 20.3 12.5 2.2
100.0
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Table 2. Estimated new breast cancer cases and
deaths in women by age in the United States, 2005
(American Cancer Society 2006).
In situ
Invasive
Age
cases
cases
Deaths
1600
Under 40
9510
1110
40 and older
56890
201730
39300
13760
Under 50
45780
5590
44730
50 and older
165460
34820
Under 65
37040
123070
17470
21450
88170
22940
65 and older
All ages
58490
40410
211240

Breast cancer screening has been recommended for several decades and the majority
of women over the age of 40 in the United States participate in screening activities
(Elmore et al. 2005).

There are rationales behind screening for a disease before it

becomes clinically evident.

They are primarily based on the principle that early

detection allows for intervention that interrupts the natural history of the disease and
prevents a detrimental outcome (Lee et al. 2004). The ideal screening test should be
noninvasive or minimally invasive, be relatively inexpensive, and have both a low falsenegative rate and low false-positive rate. In summary, the screening should produce
more benefit than harm and do so at a cost that is affordable.

Imaging Modalities for the Detection of Breast Cancer
The primary imaging modality used to detect clinically occult breast cancer is
mammography (Bluemke et al. 2004). However, due to the similarities of breast tissue
and microcalcifications, mammography has limitations in both sensitivity and specificity
which has led to the exploration of other imaging techniques. One of the most promising
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substitutions for mammography is magnetic resonance imaging (MRI), which gives
excellent soft tissue delineation with no radiation dose (Fig. 3).

Figure 3. Side view MRI of the breast with contrast showing chest and blood vessels
(MR Breast 2005).

The use of MRI for breast imaging has been approved by the United States Food and
Drug Administration (FDA) to help diagnose breast cancer since 1991 (MR Breast 2005).
Breast MRI is most commonly used to investigate breast concerns detected with
mammography, physical exam, or other imaging modalities.

MRI breast exams are

likewise extremely useful in examination of the augmented breast. This includes both the
breast implant and the surrounding tissue of the breasts. MRI is valuable for staging
breast cancer, helping to determine the most appropriate treatment, and for patient
follow-up after breast cancer treatment.
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Researchers are investigating whether breast MRI would be useful in screening
younger women at higher risk of developing breast cancer. Women younger than 40
years of age typically do not undergo mammography because of the high radiation
exposure; monthly self breast examinations are considered sufficient.

Some women,

however, do suffer from a higher risk of breast cancer due to a strong family history or a
mutated breast cancer gene, either BRCA 1 or BRCA 2. Women meeting these criteria
should undergo some form of breast imaging before the age of 40. Since most young
women have dense breast tissue, MRI may be a useful technology because of its
effectiveness in distinguishing between dense tissue and tumors. However, currently the
FDA has only approved mammography examinations to be used as a screening device for
women with no symptoms of breast cancer.

MRI is not approved by the FDA for

younger women who may have an increased risk of breast cancer.
One of mammography's shortcomings is that it loses sensitivity when screening
younger women, specifically those with dense breast tissue (Mitka 2003). Screening
mammography is less effective in identifying breast cancer in dense breast tissue because
dense breast tissue turns up as a bright region, similar to the appearance of cancerous
tumors. As women age, the breast tissue tends to become less dense, thus increasing the
effectiveness of screening mammography.
There has been recent debate about the amount of radiation dose a patient receives
from routine screening mammography (Brenner et al. 2002). Glandular doses from
screening mammography are typically low, usually less than 3 mGy of 26-30 kVp lowenergy x-rays. The dose varies depending on the size of the breast, with larger breasts
receiving a slightly higher dose.
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Because mammography consists of ionizing radiation, there is an increased risk of
developing breast cancer associated with screening exams.

This risk is due to the

exposure the breast receives from low energy x-rays which result in a factor of two
increase for developing breast cancer (Brenner et al. 2002).

However, it is highly

unlikely that the radiation risk alone is cause for major concern for mammography for
those women greater than 50 years of age.
While mammography uses low energy x-rays in imaging the breast, MRI uses
powerful magnetic fields and radio waves to create images (MR Breast 2005). It is able
to switch magnetic fields and radio waves to achieve views in any plane, yet
mammography requires re-orientation of the breast and the mammography system for
each view desired. Figure 4 depicts the normal breast imaging placement in MRI. The
total MRI exam usually consists of a variety of Tl and T2 weighted sequences, which
yields specific image orientations and specific types of contrast.

* - " • • >

K

gps*"*-

'm m
B.
Figure 4. Image A shows a recent advancement in MRI breast imaging, the CP Breast
Array Coil. This allows for bilateral breast imaging and improved differentiation
between various breast tissues. With image B, the patient is placed directly on top of the
table. The technologist has visual control of the breast position through a transparent
window (MR Breast 2005).
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Breast MRI has many benefits in helping to examine lesions and areas that may be
missed by mammography, because MRI is highly sensitive to small abnormalities. A
mammogram may reveal breast cancer in one area, but an MRI may show that the cancer
is multi-focal, meaning small tumors are present in several areas of the breast.
Determining the extent of breast cancer with MRI can help indicate the type of treatment
the patient should undergo. Breast MRI is also useful in helping to determine how far the
cancer has spread and to what areas, in addition to helping physicians determine cancer
reoccurrences in women who have already been treated for breast cancer with
lumpectomy.
While MRI has significant promise as a supplemental tool to mammography in the
diagnosis of breast cancer, it still has several hurdles to overcome in order to gain wider
acceptance and use (Mitka 2003). Breast MRI is not always able to distinguish between
cancerous and non-cancerous abnormalities, more commonly known as false-positives.
This can lead to unnecessary breast biopsies.

Also, a biopsy of an MRI detected

abnormality can be difficult. Physicians will have to learn how to use MRI to guide them
to the abnormality. Researchers and manufacturers are continuously trying to develop
new MRI systems and tools to allow for better MRI guided breast biopsy because the
abnormality found with MRI may or may not be visible with mammography.
Breast

MRI is unable to detect calcifications, while mammography can.

Calcifications are tiny calcium deposits which can indicate the presence of breast cancer,
typically associated with early stage breast cancers, such as ductal carcinoma in situ
(DCIS).
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Possibly the biggest drawback to using MRI, from a business perspective, is the cost.
The average breast MRI costs approximately $1000. This is compared to approximately
$100 per screening mammogram. Obviously to both the patient and insurance companies
paying for the imaging procedure, a breast MRI needs to show significant benefits over
mammography in order to justify the cost. Due to the current cost to benefit ratio, most
community MRI centers do not perform breast MRI.

However, new MRI systems

designed specifically for the use of breast imaging are continuously being developed but
are currently not widely available.

Magnetic Resonance Spectroscopy
MR Spectroscopy is the analysis of the shift, usually labeled as part per million
(ppm), in resonance frequency of nuclei as a result of surrounding chemical bonds
(Hendee and Ritenour 2002). Magnetic resonance spectroscopy (MRS) measures the
differences in resonance frequencies among nuclei that occupy different positions in
molecules. Each molecule resonates at a different frequency, due to their local magnetic
fields. For example, on a 3.0 T spectrometer, N-acetyl aspartate (NAA) resonates at 2.0
ppm, creatine resonates at 3.0 ppm, and choline resonates at 3.2 ppm (Brown and
Semelka 2003).
In spectroscopy, a broad range of radio frequencies is applied to the sample and a
signal containing a range of frequencies is received (Hendee and Ritenour 2002). A
Fourier transform is used on the return signal to determine what amplitude of each
frequency is contained within the signal. All molecules and compounds are detected in
the same magnetic field.
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Proton MRS has started being used to help with breast cancer diagnosis. MRS
provides the metabolic information about a visualized lesion in the breast (Lenkinski and
Katz-Brull 2005).

Thus, questionable lesions can be further examined without

unnecessary biopsies. This not only helps the radiologist in their decision making, but
also allows the patient to avoid the worry that is associated with questionable lesions.
MRS coupled with MRI allows the radiologist to not only see the image of the lesion in
the breast, but to also see the metabolic information of the lesion. A sample spectroscopy
can be seen in Fig. 5.

NAA

Cho
Cr

—

i

1

4.0

1

3.0

2.0

1

1.0

Chemical Shift (ppm)
Figure 5. A proton spectra acquired on a 3.0 T system (Achieva 2007).
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Magnetic Resonance Physics
Every proton and neutron of a nucleus has a magnetic field because of their nuclear
spin and charge distribution. When placed in an external magnetic field, the nucleus will
resonate (Bushberg et. al 2002). This is because of the properties of the nuclei spin
quantum number. Both protons and neutrons have a spin quantum number of V2 and thus,
because hydrogen has one proton, it has two energy states (Brown and Semelka 2003).
Those nuclei that have an odd number of nucleons have a magnetic moment, which is the
magnitude and direction of the magnetic field with respect to the nucleus.
A nuclear magnetic moment is generated from the nucleus of an atom since it is a
spinning charged particle (Bushong 2003). Because the magnetic moment varies based
on mass, charge of the particle and the rate at which it spins, each spin state has a
different magnetic moment. Each spin state possesses the same energy until an external
magnetic field is applied, at which point the spin states change energies.
In the external magnetic field, the spin state is typically in the lowest energy state
possible. This allows the spin states to be in equilibrium with the magnetic field. When
an electromagnetic pulse is applied to the field that has the equal energy to that of the
particles spin state energy gap, some of the particles in the lower energy state are excited
to a higher energy state. As the pulse terminates, the spins in the higher energy field
return to the lower energy state. This process of returning to the lower energy states is
what produces the magnetic resonance signal.
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Review of Related Literature
There have been a few studies conducted that couple MRI with MRS to develop a
more efficient way of detecting breast cancer.

These studies have primarily been

conducted on either 1.5 T or 4.0 T MR systems. The purpose of these studies was to
improve the specificity of MR while maintaining the sensitivity. Sensitivity is how well
an imaging system can detect subtle differences in anatomy, while specificity is the
ability to precisely identify the reason for such differences (Bushong 2003). Magnetic
resonance imaging of the breast is reported to have a sensitivity of 94-100% with variable
specificity of 37-97% (Meisamy et al. 2005). Coupling MRI with MRS should increase
the specificity.
In these studies, patients underwent an imaging protocol that consisted of a Tlweighted, a T2-weighted scans, and a spectroscopy scan. The studies measured success
in different ways. One method measured success by discovering if elevated levels of
choline reflect an incidence of breast cancer (Bolan et al. 2003). Another method tried to
discover if the elevated levels of choline could distinguish between benign and malignant
breast lesions (Roebuck et al. 1998). Another method used known results of breast
lesions and had radiologists determine the type of treatment that should be taken based on
only looking at the MR images, and then looking at the MR spectroscopy with the MR
image and determining if there should be a change in treatment (Meisamy et al. 2005).
These previous studies have shown that there is a cutoff for tCho concentration of 1.03
mmol kg"

for distinguishing between benign and malignant lesions.

A tCho

concentration greater than 1.03 mmol kg"1 suggested malignancy and a concentration less
than 1.03 mmol kg"1 suggested benignity.
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One other research method showed the

appearance of choline resonance peak based on the signal to noise ratio (SNR) of greater
than two (Huang et al. 2004). An SNR equal to or greater than two was defined as a
positive finding and a negative finding was defined as any SNR less than two.
Choline is an amine which is found in the breast. The total choline containing
compounds

(tCho)

consists of several different

choline compounds: choline,

phosphocholine, glycerophosphocholine, phosphatidylcholine, and sphingomyelin. Since
elevated levels of tCho have also been found in a variety of human tumors, a measure of
the tCho level can help radiologists determine if a lesion is cancerous (Roebuck et. al
1998). The elevated levels of tCho vary, since different amounts of tCho are produced in
the body depending on the individual.
The goal of this research is to determine whether MRI coupled with MRS is an
effective imaging protocol for the detection of breast cancer using a 3.0 T Philips
spectrometer, the highest clinically approved magnetic field strength. Success of this
study will be determined by accurately comparing mammography diagnosis with the
diagnosis from MRI coupled with MRS. Further aim of this study is to show comparable
results obtained from the 3.0 T system to a 4.0 T system. A favorable comparison
between the two would show that MRI coupled with MRS for the detection of breast
cancer is applicable today, instead of having to wait for the approval of a 4.0 T system for
clinical use.
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CHAPTER 2

MATERIALS AND METHODS
Patient Preparation
Two groups of women between 18-80 years of age were imaged on a 3.0 T Philips
Achieva MR spectrometer.

The first group consisted of those women who were

diagnosed cancer free, while the second were diagnosed with a form of breast cancer
through conventional methods, i.e. mammography. Some women had a prior incidence
of breast cancer and are currently in remission. These women were considered to be in
the diagnosed cancer free group.
A Philips Achieva 3.0 T clinical spectrometer located at the Nevada Imaging Center
Spring Valley - Amigenics was used for imaging and spectroscopy scans on all subjects.
MR imaging and MR spectroscopy measurements were made using a Philips bilateral
breast coil. The coil is designed to have the patient lie in the prone position.
The protocols used for each subject were a Tl-weighted, a T2 SPAIR SENSE scan
which is a fat suppression scan, a spectroscopy scan, dynamic thrive scan, and a thrive
post scan. The last two scans were conducted after contrast was injected into the patient.
The contrast agent was gadolinium diethylenetriamine pentaacetic acid (GDPA). GDPA
is the most commonly used contrast agent for MR Imaging. There are potential risks
involved with it. Gadolinium based contrast agents can cause nephrogenic systemic
fibrosis (NSF) which causes fibrosis in different tissues throughout the body. It most
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commonly occurs in those individuals with acute or chronic severe renal insufficiency or
dysfunction. However, the chance of developing an anaphylactoid reaction as the result
of GDPA is 0.03-0.1%. While the risk is low, no patient was imaged who had any
history of renal problems. All patients choosing to participate in the study were informed
of the potential side effects by a physician before beginning the scans. The TR and TE
used for each of the scans can be seen in Table 3.

Table 3. MR scans parameters.
Scan
TR (ms) TE(m
Tl-weighted
425
8.0
T2 SPAIR
5874
120
Spectroscopy
1500
420
Dynamic Thrive
4.2
2.1
Thrive Post
1.8
2.5

The field of view varies with each patient. The total time for the MR imaging scans
was approximately 20 minutes. Single voxel proton MR spectroscopy was performed
using a slice of interest from the T2 SPAIR SENSE scan. The long echo time was used
to help identify the choline peak, since this metabolite has a long T2 relaxation time. The
long echo time also helps to eliminate the broad components of the water resonance.
Water suppression was used to filter out the water resonance peak. With the water
suppression, the total spectroscopy scan was approximately 10 minutes. The overall scan
time varied for each patient depending on the size of the patient, the amount of tissue, the
amount of fat, and the amount of water in the breast.
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Radiologist Performance Study
Two radiologists specializing in the area of breast cancer diagnosis participated in
reading the MRI scans for this study.

Both readers were blinded to any medical

information about the participants. Current diagnosis from the last mammography scan
was not known to the radiologists.

Each patient's MR images were read by each

participating radiologist. The radiologists made their recommended diagnosis without
referring to one another, based on MR images. A recommended patient treatment followup was also provided. These results were compared to the diagnosis made from the
mammograms. The MR Spectroscopy scans recommendations were determined using
the SNR from the choline peak on the graph.
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CHAPTER 3

RESULTS
Patients
Recruitment fliers were mailed out to patients of the Nevada Imaging Center Spring
Valley - Amigenics, where the imaging scans took place. Six patients were chosen to
participate in the study, one of which was not a patient of Nevada Imaging Center Spring
Valley - Amigenics, but referred by a doctor employed with the imaging center and
familiar with this study. The mean age of the patients was 53 years with an age range of
43-69 years. All patients underwent a mammogram within the past year prior to their
MR Imaging and Spectroscopy scans. All patients underwent an MRI scan on the Philips
3.0 T Spectrometer except for the patient who was referred to us. The IRB protocol and
their rights were explained to each patient.
While a total of six patients were chosen to participate in this study, only four of the
patients' results were included in the final analysis. This is due to a variety of reasons.
The fifth patient who participated in this study was not included due to issues with
digitizing her mammograms. The patients provided their most recent mammography
scans, which were scanned into the computer database system at the Nevada Imaging
Center Spring Valley - Amigenics. During the time period when the radiologists were
preparing to read the scans, and before the scans were transferred to each of the
radiologist's computer system, the computer containing all of the patients' MRI, MRS,
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and mammography scans became inoperable. All of the scans for each patient were lost
at this time. Eventually, after rebuilding the system, the information was recovered.
However, the information for patient five was corrupt and incomplete. Much time was
spent trying to recover and restore the original scans for this patient, but some of the data
was permanently lost. The rest of the data that wasn't corrupt contained not enough
information to be able to send to the radiologists for their readings.

Since further

inconveniencing the patient was not an option this patient was removed from the study.
Patient six was excluded from this study due to major difficulties handling outside
MRI and mammography image data sets. While it was possible to examine the
mammography and MRI scans and load them into the computer system at the imaging
center, it was not possible to anonymize the scans. Since anonymizing the patient's scans
was part of the protocol to both maintain patient privacy and abide by the Health
Insurance Portability and Accountability Act (HIPAA), it was not possible to have this
patients MRI and mammography results analyzed by the radiologists. Therefore, patient
six was not included in the final results for this study.
There were also minor complications with the remaining four patients; however these
complications did not prevent them from participating in this study. Out of the remaining
four patients, only two of them, patient two and four, completed all of the scans. That is,
they had a mammography completed within the year prior to undergoing the MRI and
MRS and were able to deliver the films and radiologist's report from the mammography
scan. They also both had MRI and MRS scans that were completed with the MRI results
being read by two radiologists.
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To determine which imaging protocols were ideal for breast MR Imaging coupled
with MR Spectroscopy, different scans were investigated. Patient two completed all
aspects of the study, but an additional T2-weighted scan was also performed.

This

patient was imaged early in the study while the imaging protocols were still being
developed. At that time, it was thought the T2-weighted scan would help in identifying a
suspicious lesion for a spectroscopy scan on because water and other fluid containing
tissues are bright on this scan. The T2 SPAIR SENSE is a fat suppression scan which
also made these tissues bright. After seeing the results of the T2-weighted scan and
comparing it to the T2 SPAIR SENSE scan, it was decided to delete the T2-weighted
scan, as it offered no benefit for either the MR technician performing the scan or for the
radiologists reading the scan. It was decided to proceed with the patients from that point
forward without the T2-weighted scan. The MR technician who conducted the imaging
scans did not perform spectroscopy during the development of the protocol, and therefore
one patient did not receive it.

Once a final protocol was established with the MR

Imaging and MR Spectroscopy scans, no additional scans were conducted and all of the
scans in the protocol were performed.
The second patient who also completed all aspects of the study was patient four. This
patient was imaged during the later stages of the study. For both patient two and patient
four, the spectroscopy scan was conducted before the contrast injection so there would be
no chemical interference with the selected voxel. A physician discussed the benefits and
potential drawbacks of the contrast with each patient. A licensed technician performed
the contrast injections and a physician was present during and after the entire scan time,
in case the patient had a late reaction to the contrast agent. The mammography and MR
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Imaging with and without contrast scans were all read by two radiologists. The MR
Spectroscopy scan was analyzed by using previous literature, specifically the study
conducted by Huang et al. 2004.
The other two patients whose results were chosen to be read by the radiologists had
incomplete scans. Patient one was the first patient who was scanned as part of this study.
The patient had a mammography scan within the year prior to having the MRJ scan, but a
copy of the films was never received from the patient and repeated attempts to obtain
them were unsuccessful. It was decided to continue with the MRI scan with the hope of
receiving the mammography films at a later date, but the films were still never received
from the patient.

Also during the scan, the MR technician did not perform the

spectroscopy scan.

The results from the MR Imaging scan were analyzed by both

radiologists, but obviously no comparison can be made to the missing mammography
scans. The lack of spectroscopy prevented the verification of the BI-RADS (Breast
Imaging Reporting and Database System) diagnosis with the MRI scans.
The other patient who had incomplete results was patient three. The patient had
incomplete results for different reasons than the first patient. This patient did deliver the
mammography films to be scanned into the computer system at the imaging center. The
patient then had both the MR imaging and spectroscopy scans completed with contrast.
All scans were confirmed to be present. However, there was a problem with the data
when the computer system crashed.

While the mammography films that had been

scanned in and the MR Imaging scans with the contrast agent were able to be recovered,
the spectroscopy scan was lost. Again, a great deal of time was spent trying to discover
why the MR Imaging scans were able to be recovered while the spectroscopy was not. It
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was decided to proceed with only the mammography and MR Imaging scans. While
there were two patients who had complete results that were going to be analyzed by the
radiologists, both of those patients were thought to have either benign tumors, cysts, or
no findings, patient three was known to have a BI-RADS diagnosis of 5 with malignant
tumors present from the mammography scan. Having this patient's spectroscopy scan
would have helped to confirm the malignant tumors seen in the mammography scan by
analyzing the choline level as well as helping to measure the effectiveness of MR
imaging coupled with spectroscopy. Table 4 lists the different BI-RADS categories and
the respective diagnosis and criteria for each one.

Table 4. BI-RADS Scores (American College of Radiology 2003).
Category
Diagnosis
Criteria
Not enough information to
0
Incomplete
make a diagnosis
1

Negative

Nothing to comment on

2

Benign

Definite benign finding

3

Probably benign

4

Suspicious abnormality

Finding has high probability
of being benign
Reasonable probability of

5

. .
~ ,.
TT. , .
Highly suspicious of malignancy

6

Known biopsy proven malignancy Known to be malignant

being malignant
High probability of being
~! r

In regards to patient three it should be noted that mammography did not miss the
malignant tumors.

Upon talking to the patient about their medical history, it was

discovered the patient had not undergone a mammography scan in over five years.
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MR Imaging and Spectroscopy Results
Table 5 shows the results of each patient scanned. As can be seen in the table, only
two of the four patients completed all aspects of the study. The mammography BI-RADS
reading, two MRI BI-RADS reads by radiologists, and the spectroscopy level are all
included. The spectroscopy level is determined using the SNR. An SNR of greater than
or equal to 2.0 indicates a positive finding and an SNR of less than 2.0 indicates a
negative finding.

Any of the exams where patients' results were unavailable or not

completed are marked with an X.

Table 5. Mammography and MRI findings using BI-RADS score. MRS
findings used SNR score. MR Imaging scans were read by two radiologists.
Patient
Mammogiraphy MR Imaging 1 MR Imaging 2 MR Spectroscopy
X
Patient 1
X
3
3
Patient 2
2
2
2
1.3
X
Patient 3
5
5
5
Patient 4
1
1
1
0.1
An X signifies exam either not completed or unavailable

Patient 1 received a BI-RADS score of 3 from each radiologist reading the MRI
scans. Mammography and spectroscopy were unavailable for this patient. The BI-RADS
score of 3 indicates that lesions are present in the breast and have a high probability of
being benign.

Figure 6 shows selected slices from each of the scans the patient

underwent. The bright spots in the images indicate the lesions in the breast and help the
radiologist diagnosis. Since the tumors are probably benign, a six month follow-up is
recommended.
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Figure 6. Patient 1 images from each scan performed. A) is slice 34 from the Tlweighted scan. B) is slice 34 from the T2 SPA1R scan. C) is slice 317 from the Dynamic
Thrive scan. D) is slice 116 from the Thrive Post scan.

Patient 2 received a BI-RADS score of 2 from the radiologist reading the
mammography scan and a BI-RADS score of 2 from each of the radiologists reading the
MRI scans. The BI-RADS score of 2 indicates lesions or calcifications are present in the
breast but are definitely benign. Figure 7 shows selected slices from each of the MR
scans the patient underwent. The bright spots in the images indicate the presence of the
benign lesions in the breast. Because the tumors are known to be benign, annual routine
screening is recommended, corresponding to the SNR of 1.3 for the spectroscopy scan.
Spectroscopy results were only available for two of the four patients. The patients
whose results were available were patient 2 and 4 as listed in Table 5. The results from
the MR image for patient 2 show the possibility of tiny cysts within the selected voxel.
The spectroscopy conducted on this patient shows a SNR of 1.3, indicating a negative
finding. Based on the mammography scan, both radiologists' reads of the MR imaging
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scans, and the low SNR level, a recommendation of continued annual screening
mammography was recommended. Figure 8 shows the MR image of patient 2 as well as
its corresponding MR Spectroscopy scan.

Figure 7. Patient 2 images from each scan performed. A) is slice 34 from the Tlweighted scan. B) is slice 34 from the T2 SPAIR scan. C) is slice 405 from the Dynamic
Thrive scan. D) is slice 95 from the Thrive Post scan.

Figure 8. The MR image and spectroscopy results for patient 2 are shown in A) and B).
The MR image in A) shows the voxel that was chosen outlined in the box on the left
breast. In B), the choline peak is highlighted in the spectroscopy graph at 3.2 ppm, the
position of tCho in a 3.0 T spectrometer. The SNR of 1.3 indicates a negative finding.
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Patient 3 received a BI-RADS score of 5 from the radiologist reading the
mammography scan and a BI-RADS score of 5 from each of the radiologists reading the
MRI scans. The BI-RADS score of 5 indicates lesions are present in the breast and have
a high probability of being malignant. MR images can be seen in Figure 9. A fairly large
tumor can be seen in the left breast in the T2 SPAIR scan. The same tumor is seen even
more clearly in the two contrast scans along with several other small lesions. For this
diagnosis, appropriate action should be taken, whether it includes immediate surgery
without biopsy, oncology treatment, or a different treatment method. Ultimately, the
treatment method will be different for each patient. Spectroscopy was unavailable for
this patient. Figure 9 shows selected slices from each of the scans the patient underwent.

Figure 9. Patient 3 images from each scan performed. A) is slice 34 from the Tlweighted scan. B) is slice 34 from the T2 SPAIR scan. C) is slice 317 from the Dynamic
Thrive scan. D) is slice 77 from the Thrive Post scan.

Patient 4 received a BI-RADS score of 1 from the radiologist reading the
mammography scan and a BI-RADS score of 1 from each of the radiologists reading the
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MRI scans.

The BI-RADS score of 1 indicates there are no lesions or suspicious

calcifications present in the breast and therefore nothing to comment on.

Since no

masses are seen, annual routine screening is recommended, corresponding to the SNR of
0.1 for the spectroscopy scan. Figure 10 shows selected slices from each of the scans the
patient underwent.

Figure 10. Patient 4 images from each scan performed. A) is slice 34 from the Tlweighted scan. B) is slice 34 from the T2 SPAIR scan. C) is slice 317 from the Dynamic
Thrive scan. D) is slice 77 from the Thrive Post scan.

The results from the MR image for patient 4 identified no tumors or cysts.
Spectroscopy was performed on the patient and an SNR of 0.1 was found, indicating a
negative finding. Based on the mammography scan and both radiologists' reads of the
MR imaging scans, and the low SNR level, a recommendation of continued annual
screening mammography is still recommended.

Figure 11 shows the MR image of

patient 4 as well as its corresponding MR Spectroscopy scan.
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Figure 11. The MR image and spectroscopy results for patient 4 are shown in A) and B).
The MR image in A) shows the voxel that was chosen outlined in the box on the left
breast. In B), the choline peak is highlighted in the spectroscopy graph at 3.2 ppm, the
position of tCho in a 3.0 T spectrometer. The SNR of 0.1 indicates a negative finding.

It is also possible to have a false positive with MR Spectroscopy. An SNR of greater
than 2 can still be a negative finding, but it would be unknown whether it was a negative
finding until after a biopsy was performed. A high SNR indicating the presence of a
tumor could be due to several reasons, such as interference from other breast tissue in the
voxel or the voxel not being an appropriate size for the suspected lesion.

Protocols
The breast MRI and MRS protocol took some time to develop because the Nevada
Imaging Center Spring Valley - Amigenics does not offer breast MRI or MRS. A
mixture of scans were initially used, but eventually discarded because they either
revealed no beneficial information or had similar parameters to other scans and were
therefore unnecessary. After several different scans were added or subtracted from the
protocol, the researcher for this study decided on the final protocol that consisted of a Tlweighted, T2 SPAIR, Spectroscopy, Dynamic Thrive, and a Thrive Post scan. All four
patients underwent each of the scans with the exception of patient 1 who did not have
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spectroscopy conducted. Patient 3 completed all of the scans but the spectroscopy was
lost when the computer system was inoperable.
Figures 6, 7, 9, and 10 show selected slices from each of the patients. The slices
represented for each patient were chosen based on the image from each scan showing the
most detail. Image A) in each of the figures is the Tl-weighted scan. Each of the Tlweighted images appears bright, emphasizing the fat in the breast. The fat is easily seen
in each patient, enabling the radiologist when looking at other scans to easily see if a
potential lesion is actually fat by referring to the Tl-weighted scan. Water and other
fluids in the breast appear as dark intensity in each of the figures.
Image B) in each of the figures is the T2 SPAIR scan. Fat appears as a dark intensity
and water and other fluids appear as bright intensities.

The T2 SPAIR is a fat

suppression scan which helps to emphasize the water in the breast as well as enhance any
lesions that might be present. Since fat and water have different resonances, the fat is
suppressed by introducing a prepulse to eliminate the quadrupole effects on fat
suppression. The fat suppression adds to the overall scan time, but is vital in order to
achieve the image quality seen in the images. With the fat suppressed, lesions appear
bright and are easier to differentiate from water and other fluids that are present.
Image C) in each of the figures is the Dynamic Thrive scan. This is a Tl scan that
has had gadolinium added as a contrast agent. The dynamic thrive scan is a quick scan
showing the uptake of the agent in the breast almost immediately after it has been
administered.

Since the contrast agent is typically seen in the malignant and benign

lesions in the breast before any other areas, a quick scan can help the radiologist easily
differentiate the lesions from other areas in the breast.
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Image D) in each of the figures is the Thrive Post scan. It is also a Tl scan aided with
the use of a gadolinium contrast agent. This scan is an appropriate follow-up scan to the
Dynamic Thrive scan because it still has the benefits of the contrast agent uptake in the
lesions, but also the contrast has been absorbed by the rest of the breast by this point in
the scanning protocol. It offers more detail to the overall breast while still showing the
lesions as bright spots.
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CHAPTER 4

CONCLUSIONS
MR imaging for the detection of breast cancer has shown promise but there are issues
still associated with it, such as time of exam, cost, and false positives, that overall make it
an imaging modality that does not currently offer the screening benefits of
mammography. The use of MR spectroscopy for the detection of breast cancer is still a
fairly new concept and is not widely utilized. However, MR imaging coupled with MR
spectroscopy is showing promise.
While there were only a small number of patients scanned for this study, there are
positives voiced by the patients. All of the patients liked the fact that the MRI offered an
alternative to the breast compression associated with mammography scans in order to
produce the best possible image. The ease of the entire exam was also cited as a positive
by all patients. The patients also expressed enthusiasm with regards to the fact that there
is no radiation dose from the MR imaging or spectroscopy exams as is the case with
mammography.
There were also some negatives about the exam that some of the patients noted. The
primary concern about the exam was the length of time. While a mammography scan can
take as little as 10 or 15 minutes, the MRI and MRS exams take approximately 30-40
minutes. The patients that received a contrast injection also cited this part of the exam as
a negative. Specifically, the patients didn't like the fact that the needle was placed into
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their hand during the prep before the scan took place, and then they had to wait until the
part of the scanning protocol to receive the injection before the needle was removed. The
MRI bore can also get extremely loud during some of the exams and this was noted as
more of an annoyance as opposed to a negative.
One major complication with regards to this study was the lack of patients. This was
due to several reasons. The most common complaint from potential patients was the time
the imaging and spectroscopy scans would take place. Most of the exams had to be
conducted at night. This was because the Philips 3.0 T spectrometer is in high demand
due to the rarity of the magnetic strength in the Las Vegas valley and the quality of
images that can be seen from it. The MRI is in use seven days a week for approximately
16 hours a day, leaving only a small window at night when it was available to be used for
research purposes. Many potential patients said the only time available for them to
volunteer for the study was during normal day time hours. Therefore the time of the
exams was a turnoff for many potential patients. Several potential patients were unable
to be imaged due to metal objects being located inside their bodies and the concern the
magnets could potentially cause physical harm.
Because of the small number of patients and the incomplete scans for a couple of
them, it is hard to measure the diagnostic performance of MR spectroscopy. The two
patients who completed all the scans, mammography, MR imaging, and MR
spectroscopy, show MR imaging and spectroscopy to be effective methods. Both patients
MR images read by the radiologists confirmed the recommendations of the radiologist
who read the mammography scans.

The results from the spectroscopy graphs also
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confirmed these results, indicating that MR imaging coupled with spectroscopy is an
effective imaging modality for diagnosing breast cancer.
MR Spectroscopy helps to determine the diagnosis and recommended follow-up for
the patient, but does have a drawback seen in this study. Patient four had been diagnosed
as a BI-RADS 1 from the mammography scan, indicating a negative finding. Since a
negative finding means there is nothing to report, it is difficult to run spectroscopy if
there are no lesions present. The use of MRI does help to see lesions that may go
undetected with mammography, but could also produce the same result. In these cases
where the patient clearly has no lesions present and is a negative finding, it is probably
not worth the either the MR technologist or the patients' time to undergo this scan. More
research is needed to determine if this is valid conclusion or just a rare case that appeared
in this study.
Though the number of patients was low, some findings can be noted. Both of the
radiologists were in agreement with each other as to the BI-RADS diagnosis. While MRI
for the detection of breast cancer is not widely used, radiologists coming to the same
conclusion while not previously seeing a large number of MRI breast scans shows
promise that these image sets are not too complicated to analyze for the inexperienced.
This is especially a good sign since the four patients each had a different diagnosis, yet
the radiologists still came to the same conclusions.
The use of the gadolinium contrast agent is a definite must for any breast MRI
protocol.

The contrast agent uptake in the breast by the lesions clearly helps the

radiologist identify not only obvious larger lesions seen in the Tl-weighted and T2
SPAIR scans, but also smaller lesions that may have gone unnoticed. The Tl-weighted
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and T2 SPAIR scans should also be included in the protocol due to the benefits of
differentiating the tissue relaxation times in the breast. The fat tissue appearing as a
bright intensity in the Tl-weighted scan and water and other fluids appearing as bright
intensity in the T2 SPAIR again help to differentiate the different tissues and fluids that
make up the breast and aid the radiologist in making a better diagnosis and recommended
follow-up.
Previous studies of MR imaging coupled with spectroscopy for the detection of breast
cancer have been primarily conducted on 1.5 T spectrometers, with a few studies
conducted on a research based 4.0 T spectrometer. Obviously the number of patients
used in the study is not ideal, and a larger volume would produce more complete results,
the few patients that imaged show positive results and incentive to continue the research
on a broader scale. The MR image exams were consistent with the mammography BIRADS results.

The spectroscopy results both confirmed that any suspected lesions

discovered and analyzed within the voxel area were negative findings.
There needs to be continued research conducted with MR Imaging coupled with MR
Spectroscopy, but the use of a contrast agent is essential for helping to emphasize
potential lesions in the breast. Continued research on a 3.0 T spectrometer will help to
conclude whether MR Imaging coupled with Spectroscopy is an effective imaging
modality for the detection of breast cancer.
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NOTICE TO All XESEARCHEKS:
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Please he aware that a protocol violation (e.g., failure to submit a modification for gnf change) ofan
IRB approved protocol may result in mandatory remedial education, additional audits, re-consenting
subjects, researcher probation suspension of any research protocol at issue, suspension of additional
existing research protocols, invalidation of all research conducted under the research protocol at
issue, andfurther appropriate consequences as determined by the IRB and the Institutional Officer.

DATE:

January 8, 2006

TO:

Dr. Phillip Patton, Health Physics

FROM:

Office for the Protection of Research Subjects

RE:

Notification of IRB Action by Dr. Charles Rasmussen, Co-Chair < * ^ / J o S
Protocol Title; Investigation of Magnetic Resonance Imaging and Spectroscopy for
the Detection of Breast Cancer
Protocol #-,0611-2139

This memorandum is notification that the project referenced above has been reviewed by the UNLV
Biomedical Institutional Review Board (IRB) as indicated in regulatory statutes 45 CFR 46. The
protocol has been reviewed and approved.
The protocol is approved for a period of one year from the date of IRB approval. The expiration date
of this protocol is 2,2008. Work on the project may begin as soon as you receive written notification
from the Office for the Protection of Research Subjects (OPRS),
PLEASE NOTE:
Attached to this approval notice is the official Informed Consent/Assent (IC/IA) Form for this study.
The IC/IA contains an official approval stamp. Only copies of this official IC/IA form may be used
when obtaining consent. Please keep the original for your records.
Should there be any change to the protocol, it will be necessary to submit a Modification Form
through OPRS. No changes may be made to the existing protocol until modifications have been
approved by the IRB.
Should the use of human subjects described in this protocol continue beyond 2, 2008 it would be
necessary to submit a Continuing Review Request Form 60 days before the expiration date.
If you have questions or require any assistance, please contact the Office for the Protection of Research
Subjects at OPRSHumanSubiects@unlv.edu or call 895-2794.

Office for :he Proietrion of Research Subject;
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UNLV
LNFORMED C O N S E N T
Department of Health Physics
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TITLE OF STUDY: Investigation of Magnetic Resonance Imaging and Spectroscopy for the
Detection of Breast Cancer
INVESTIGATOR(S): Robert Etnire. Phillip Fatten
CONTACT PHONE NUMBER: 702-895-3555 (Phillip Patton), 702-869-S889 (Rob Etnirc)

Purpose of the Study
You are invited to participate in a research study. The purpose of this study is to investigate Magnetic
Resonance Imaging (MRJ) as a new methodology for identifying breast cancer using various imaging
procedures.
Participants

You are being asked to participate in the study because your mammography scans have indicated the
possibility of breast cancer, or you are healthy and have not been previously diagnosed with breast
cancer and are between the ages of 18 and 80 with no known medical conditions such as pregnancy,
metal implants, claustrophobia, etc., that would prevent you from being imaged by MRI.
Procedures

If you volunteer to participate in this study and are selected, you will be asked to do the following: lie
on your stomach for approximately 45-60 minutes while the imaging procedure is occurring and
complete a questionnaire about your medical history and a questionnaire about the procedure.

Benefits of Participation
There may not be direct benefits to you as a participant in this study. However, we hope to leant that
Magnetic Resonance Imaging coupled with Magnetic Resonance Spectroscopy is effective for the
diagnosis of breast cancer, thus reducing the radiation exposure women receive from their annual
mammograms.
Risks of Participation
There are risks involved in all research studies. This study may include minimal risks. It is possible
that some participants may experience claustrophobia during the procedure. Additionally, participants
may fall while getting on or off the imaging table. Subjects may feel uneasy about the medical history
questionnaire as well.
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INFORMED CONSENT
Department of Health Physics

TITLE OF STUDY: investigation of Magnetic Resonance Imagine and Spectroscopy for the
Detection of Breast Cancer
INVESTIGATORS): Robert Etnire, Phillip Patton
CONTACT PHONE NUMBER: 702-895-3555 (Phillip Patton), 702-869-588') (Rob Etnire)

Cost •/Compensation
There will not be a financial cost to you to participate in this study other than time and money needed
to travel to and from she imaging center. The study will take approximately 45 - 60 minutes of your
time. You will not be compensated for your time. The University of Nevada, Las Vegas may not
provide compensation or free medical care for an unanticipated injury sustained ax a result of
participating in this research study.
Contact Information
If you have any questions or concerns about the study, you may contact Robert Etnire at 702-8695889 or Phillip Patton, PhD at 702-895-3555. For questions regarding the rights of research subjects,
any complaints or comments regarding the manner in which the study is being conducted, you may
contact the UNLV Office for the Protection of Research Subjects at 702-895-2794.

Voluntary Participation
Your participation in this study is voluntary. You may refuse to participate in this study or in any pan
of this study. You may stop participating in this study at any time for any reason without prejudice to
your relations with the university. You are encouraged to ask questions about this study at the
beginning or any time during the research study.
Confidentiality
All information gathered in this study will be kept completely confidential. No reference will be made
in written or oral materials that could link you to this study. All records will be stored in a locked
facility at UNLV for at least 3 years after completion of the study. After the storage time the
information gathered will be shredded.
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Department of Health Physics

TITLE OF STUDY; Investigation of Magnetic Resonance Imaging and Spectroscopy for the
Detection of Breast Ca ncer
INVKSTIGATOR(S): Robert Etnire, Phillip Pattern
CONTACT PHONE NUMBER: 702-89S-3SSS (Phillip Pattoril, 702-869-S889 (Roh Etnire)

Participant Consent:
I have read the above information and agree to participate in this study. I am at least \V> years of age
with no medical conditions (pregnant, metal implants, claustrophobia, etc.) that prevent me from being
imaged using a magnetic resonance imaging spectrometer. A copy of this form has been given to me.

Signature of Participant

Date

Participant Name (Please Print)
Participant Note: Please do not sign this document if the Approval Stump is missing or is expired.
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Imaging and Spectroscopy Scans
1. Select 'Patient' on the menu bar.
2. Select'New Exam.'
3. Enter the following information:
a. Patient's coded name.
b. Registration number.
c. Patient's date of birth (MM/DD/YYYY).
d. Patient gender as female.
e. Patient's weight (in kg).
f. Any additional comments.
g. The other fields can be left blank.
4. Clink'Enter.'
5. Click 'Proceed.' The system will not automatically switch to scan mode.
6. Select the 'Hospital' folder in the Exam Cards.
7. Select the folder 'User Defined 3.'
8. Scroll down and select the 'Breast' folder.
9. Select the first scan list 'Breast.'
10. Copy the scans and paste them in the Exam Cards.
11. Delete all scans except the Survey, RefSBrst, sTlW_TSE_Tra, sT2W_TSE_Tra,
DYNTHRIVE SENSE, THRIVEHR POST SENSE. These are the only
imaging scans that are needed.
12. Next, add the spectroscopy scan.
13. Select the 'Hospital' folder in the Exam Cards
14. Select the 'Thorax' folder.
15. Copy and paste the 'Breast Spectroscopy' scan into the Exam Cards, placing it
after the sT2W_TSE_Tra scan and before the DYNTHRIVE SENSE scan. The
scan is named SV_PRESS_270.
16. In the Exam Cards, click on 'Status' for the Survey scan to open up the scan.
Click 'Proceed' to start the Survey scan. The Survey scan will now begin.
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17. When the Survey has finished, click on 'Status' in the Exam Cards for the
RefSBrst to open up the scan. Click 'Proceed' to start the Ref_SBrst scan. The
RefSBrst scan will now begin.
18. When the RefSBrst has finished, click on 'Status' in the Exam Cards for the
s T I W T S E T r a to open up the scan. Select the 'Parameter Editor' on the Exam
Cards Toolbar. Under the 'Initial' tab, use the Survey scan as a guide and adjust
the field of view (FOV) to the size of the breast. Under the 'Geometry' tab, turn
SENSE off and change the Matrix scan to 256. Click 'Proceed' to start the
s T I W T S E T r a scan. The sTlW_TSE_Tra scan will now begin.
19. Repeat the steps used for the s T I W T S E T r a for the T2 SPAIR SENSE,
DYNTHRIVE SENSE, and THRIVEHR POST SENSE. The previous scans
do not need to be finished to edit the following scans, with the exception of the
S V P R E S S 2 7 0 scan. If the previous scan has not finished and the edit has been
completed for the following scan, click 'Proceed' for this scan. It will start
automatically once the previous scan has finished.
20. Once the T2 SPAIR SENSE has been completed, click on 'Status' in the Exam
Cards for the S V P R E S S 2 7 0 to open up the scan. Select a slice from the T2
SPAIR SENSE that shows the suspicious area where the spectroscopy will be
performed. A red box will appear in about 10-20 slices. This is the voxel box
where the spectroscopy will be performed. Try to conform the voxel box to the
exact size of the suspected area. Click 'Proceed' to start the SVPRESS270
scan. The SV_PRESS_270 scan will now begin.
21. The software will automatically adjust for the water suppression.
22. Following the water suppression, the scan will now begin.
23. When the S V P R E S S 2 7 0 scan has been completed, the contrast should be
administered. Once the injection is complete, start the DYNTHRIVE SENSE
scan. The scan preparation should have already been completed as stated in step
19.
24. Once the DYNTHRIVE SENSE scan has been completed, the THRIVEHR
POST SENSE will begin. This is the last scan in the protocol.
25. Once the protocol is completed, click on the 'Advance Processing Button' next to
the patient name.
26. Double click on the figure of the peaks. This will load the spectroscopy curve
into the main window.
27. Click 'Run Script.' This will load the graph for the voxel.
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The protocol being used consists of the following scans
Survey
RefSBrst
Reference scan for bilateral SENSE Breast coil
-The sensitivity information obtained in this scan is used for all
CLEAR reconstructions during the entire exam.
Tip:
If large patient movement has occurred, the reference scan should
be repeated.
sTlW_TSE_ Tra
A T I weighted turbo spin echo (TSE) sequence of the breast
- The V stands for single shot
- Due to CLEAR, the axillae can also be clearly visualized
- Randomized shots are used to minimize motion artifacts
T2 SPAIR SENSE
A T2 fat suppression scan
SVPRESS270
MR spectroscopy scan
DYNTHRIVE SENSE
Tl weighted scan with contrast
THRIVE HR POST SENSE
T1 weighted scan with contrast

Patient Positioning
1. Place the couch in the parking position by using the Out/Down tumble switch on
the control panel. If imaging a heavy patient, do not place the couch in the
parking position. Instead, place a couch about 15 cm from its lowest point.
2. Place the breast coil on the couch. Do not plug the coil into the scanner at this
time. For comfort, place a few pillows at the head of the couch for the patient to
rest their head on and place the coil directly behind these pillows. Place the breast
mattress directly behind the coil. Add any other mattress as needed for patient
comfort. Be sure the patient is as comfortable as possible to minimize motion
artifacts. Blankets or sheets may be used as the room may become cool during
the procedure.
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3. Have the patient remove any metal items they are wearing. Give the patient a
gown to wear with the opening in the front. The patient must not wear a shirt or
bra during the procedure. Give the patient earplugs for their protection. The
acoustic noise levels may cause some discomfort for patients without earplugs.
4. Have the patient lie down in the prone position on the couch. The breasts should
be placed in holes in the coil and hang freely. The gown can hang on the sides of
the coil, but cannot be in the coil holes.
5. Press the 'light visor' button on the control panel. This will activate the laser
beams. Raise the couch using the Up/In tumble switch. Using the laser beams,
place the patient so the breasts lie in the middle of the illuminated cross. Press
'Travel-to-scanplane' button on the control panel. The laser beams will turn off
automatically. Use the Up/In tumble switch to place the patient into the tube.
The couch will stop moving once the isocenter has been reached. The coil may
now be plugged into the scanner.
6. Once all the scans have finished, remove the patient from the tube. Use the
Out/Down tumble switch on the control panel until the couch is in the parking
position. If imaging a heavier patient, stop the couch at about 15 cm above the
lowest level.
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MRI DEFINITION OF TERMS
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CLEAR
• Stands for Constant LEvel AppeaRance
• Provides a superb uniformity correction
• It is automatically implemented in all SENSE protocols
• Requires that a reference scan be performed. The reference scan provides a
sensitivity map of the coil enabling the system to calculate the exact signal
contribution to each pixel of the image.
SENSE
• Stands for SENSitivity Encoding
• Potential benefits include:
• Shorter scan times
• Higher temporal resolution
• Improved spatial resolution
• Less motion and susceptibility artifacts
SPAIR
• Stands for SPectral Attenuated Inversion Recovery
• Fat suppression technique
SNR
•
•

Stands for Signal to Noise ratio
Measure of image quality

THRIVE
• Stands for Tl High Resolution Isotropic Volume Excitation
• Used with contrast for dynamic studies
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COPYRIGHT PERMISSION LETTERS
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National Cancer Institute
Original Message
From: N C I Cancer.gov Staff <cancer.gov_staff@mail.nih.gov>
To: rel82@aim.com; Rel82@aol.com
Sent: Fri, 9 Mar 2007 11:28 a m
Subject: R E : Cancer.gov Inquiry - Copyright Information
This follow-up message is in response to the e-mail you recently sent
to the
National Cancer Institute's (NCI) Web site, http://www.cancer.gov,
regarding
acknowledgement requirements for the use of content on our site. We
apologize
for the delayed response. Both of the illustrations you mentioned
(http://www.cancer.gov/cancertopics/wyntk/breast/page2 and
http://training.seer.cancer.gov/ss moduleOl breast/unit02 secOl anatomy
_Jrtrnl)
are in the public domain and may be used freely. Acknowledgement of
the sources
is appreciated, but not required.
We prefer the following format when referencing content in the "What
You Need To
Know About(tm) Cancer" publications:
National Cancer Institute. What You Need To Know About(TM) Breast
Cancer
(http://www.cancer.gov/cancertopics/wyntk/breast). Posted 07/30/2005.
Source acknowledgement for information from the SEER Training Web site
may be
stated as follows:
From http://www.training.seer.cancer.gov; funded by the U.S. National
Cancer
Institute's Surveillance, Epidemiology, and End Results (SEER) Program,
via
contract number N01-CN-67006, with Emory University, Atlanta SEER
Cancer
Registry, Atlanta, Georgia, U.S.A.
We hope this information is helpful.

National Cancer Institute Staff
NOTE: You may get an error message when clicking on the URL link(s) in
this
e-mail. If you copy and paste the full URL into your browser window,
you should
not have a problem opening the link.

From: re!S2@aim.com

[mailto:rel82@aim.com]
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Sent: Monday, March 05, 2007 7:31 PM
To: NCI Cancer.gov Staff
Subject: Re: Cancer.gov Inquiry - Copyright Information
Thank you for your help.

I look forward to your reponse.

Robert Etnire

Original Message
From: cancer.gov staff@rnail.nih.gov
To: RelW@aol.com
Sent: Mon, 5 Mar 2007 1:06 PM
Subject: RE: Cancer.gov Inquiry - Copyright Information
This message is in response to the e-mail you recently sent to the
National Cancer Institute's (NCI) Web site, http://www.cancer.gov,
regarding the use of content posted on our site.
We are trying to find out if the two illustrations you mentioned are in
the public domain. If they are in the public domain, no copyright
forms
will need to be completed. If the illustrations are not in the public
domain, we will try to provide contact information for the owner of the
illustrations.
We apologize for the delay and will send a response as soon as
possible.
Thank you for your patience.

National Cancer Institute Staff
NOTE: You may get an error message when clicking on the URL link(s) in
this e-mail. If you copy and paste the full URL into your browser
window, you should not have a problem opening the link.
Original Message
From: Rel82@aol.com [mailto:Rel82@aol•com]
Sent: Wednesday, February 28, 2007 11:34 AM
To: NCI Cancer.gov Staff
Subject: Cancer.gov Inquiry - Copyright Information
Message: To whom it may concern:
I am a graduate student at UNLV. I am currently working on my thesis
and I would like to include two images from your website in my research
paper. In order to do so, I would need permission from you to use the
image. The images I would like to use can be found at these websites:
http://www.cancer.gov/cancertopics/wyntk/breast/page2 and
http://trainirig.seer.cancer.gov/ss moduleOl breast/unit02 secOl anatomy
html. I can send the
signed, and mailed to
page will be included
possible,
can you please send a
your decision. Also,

copyright page that would need to be filled out,
me as an attachment in an email. The copyright
in my thesis granting me permission. If
reply to my email address letting me know about
if you do grant me permission, the sooner I
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receive the filled out copyright form, the better.
advance
for your help.
Robert Etnire
7937 Terrace Rock Way #101
Las Vegas, NV 89128
re!82@aol.com
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Thank you in

American Cancer Society
March 12, 2007
American Cancer Society
Attention: Reprints
To w h o m it may concern,
My n a m e is Robert Etnire and I am a graduate student at the University of Nevada, Las
Vegas. I am currently working o n my thesis and will like to include some information from
your website in it. I am researching the use of MRI coupled with MRS on a 3.0 T
spectrometer for the detection of breast cancer. The research is in support of my thesis to
earn my Master of Science degree in Health Physics.
I am requesting to use a table from the pdf file titled "Breast Cancer Facts and Figures 20052006." Specifically, I am requesting the use of Table 2. Estimated N e w Breast Cancer Cases
and Deaths in Women by Age, US, 2005. T h e document is located at the web address:
http://\\n\^v.cancer.ofg/downloads/STT/CAFF2005BrFacspdf"2005.pdf and a copy of the
table is on page 3 of this document. Page 3 from this document has been included as part
of the fax.
T h e table will be included in its entirety in my thesis as background information detailing the
n u m b e r of people by age stricken with breast cancer, as well as the number of deaths from
it. T h e table will be cited both in the text and in a references page at the end of the thesis.
In addition, a copyright page will be included in a separate section, detailing that permission
was granted from the American Cancer Society to reprint the table.
T h e copyright page that I need filled out is included as part of this fax. It will either need to
be mailed to me since it requires a signature, or scanned into a document and emailed. If
the table from the document requested is public domain, then no copyright form is needed.
However, I still need confirmation stating the document and the table requested is public
domain. Proper citation will still be given as previously mentioned.
A final copy of the thesis will be shelved in the library at UNLV, as well as placed on
microfilm. T h e thesis will not be sold, but may be referenced to in the future by other
researchers.
T h a n k you for your help regarding my thesis. If there is any other information needed,
please feel free to contact me by any of the methods listed below. Also, if there is anything I
can d o to speed up the request process, please let me know that as well. T h a n k you again.
Sincerely,
Robert Etnire

7937 T E R R A C E R O C K WAY #101
LAS V E G A S , N V 89128
P H O N E : 702-869-5889
EMAIL: RE182@AOL.COM
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